Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Stage IVa Nasopharyngeal Carcinoma

Launched by JIANGSU CANCER INSTITUTE & HOSPITAL · Jun 21, 2023

Keywords

ClinConnect Summary

This clinical trial is looking to better understand stage IVa nasopharyngeal carcinoma, a type of cancer that affects the area behind the nose. The researchers want to find specific markers, known as biomarkers, that can help predict how the disease will progress and how well treatments might work. This study will involve patients who have just been diagnosed with this type of cancer and have no signs of the cancer spreading to other parts of the body.

To participate in this trial, patients should be between the ages of 18 and 75, and they need to have a confirmed diagnosis of stage IVa nasopharyngeal carcinoma. It's important that they haven't received any treatment aimed at relieving symptoms, known as palliative care. Those who join the trial will help researchers gather valuable information that could lead to better treatment options in the future. The trial is currently not recruiting participants, but it aims to provide insights that could improve care for patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with newly histologically confirmed stage IVa nasopharyngeal carcinoma
• • 2. No evidence of distant metastasis (M0)
• • 3. Written informed consent
• Exclusion Criteria:
• • Treatment with palliative intent